AcouSort AB (SE:ACOU)
:ACOU
Want to see SE:ACOU full AI Analyst Report?
Top Page
AcouSort AB
(ACOU)
Select Model
Select Model
Rating:53Neutral
Price Target:
kr5.00
▲(89.39% Upside)
Action:Reiterated
Date:04/30/26
The score is held down primarily by weak financial performance—ongoing losses, negative margins, and sustained cash burn—despite the benefit of having no reported debt. Technicals are a meaningful offset, showing a strong uptrend and positive momentum. Valuation remains constrained because losses drive a negative P/E and there is no dividend yield data.
Positive Factors
Proprietary acoustofluidic technology
AcouSort’s acoustofluidic platform is a differentiated, integration-friendly technology serving cell therapy, diagnostics and research workflows. That product-market fit across expanding end markets supports durable commercial opportunity and potential long-term OEM partnerships.
Negative Factors
Persistent losses and negative margins
Multi-year negative net income and deeply negative operating and gross margins indicate fundamental profitability issues. Without structural margin improvement, the company cannot self-fund growth, limiting reinvestment capacity and undermining long-term returns regardless of revenue gains.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary acoustofluidic technology
AcouSort’s acoustofluidic platform is a differentiated, integration-friendly technology serving cell therapy, diagnostics and research workflows. That product-market fit across expanding end markets supports durable commercial opportunity and potential long-term OEM partnerships.
Read all positive factors
AcouSort AB (ACOU) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr105.61M
Dividend YieldN/A
Average Volume (3M)29.24K
Price to Earnings (P/E)―
Beta (1Y)0.20
Revenue Growth44.67%
EPS Growth33.10%
CountrySE
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.65
Shares Outstanding21,163,902
10 Day Avg. Volume27,764
30 Day Avg. Volume29,240
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.27
Price to Sales (P/S)7.79
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)kr10.70M
AcouSort AB Business Overview & Revenue Model
Company Description
AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instr...
How the Company Makes Money
null...
AcouSort AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.85M | 4.74M | 10.55M | 4.96M | 3.01M |
| Gross Profit | -14.50M | 4.77M | 8.39M | 2.91M | 548.00K |
| EBITDA | -14.33M | -15.89M | -16.70M | -12.86M | -11.46M |
| Net Income | -12.15M | -15.08M | -17.09M | -13.21M | -12.38M |
Balance Sheet | |||||
| Total Assets | 17.89M | 12.32M | 34.51M | 42.66M | 36.56M |
| Cash, Cash Equivalents and Short-Term Investments | 6.29M | 3.57M | 23.99M | 33.97M | 31.52M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.59M | 3.86M | 10.38M | 22.54M | 3.54M |
| Stockholders Equity | 16.30M | 8.46M | 24.14M | 20.11M | 33.02M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -19.84M | -31.77M | 2.95M | -12.23M |
| Operating Cash Flow | -16.78M | -18.81M | -31.56M | 3.96M | -10.92M |
| Investing Cash Flow | -488.00K | -1.02M | -1.16M | -1.01M | -1.31M |
| Financing Cash Flow | 18.98M | -157.00K | 22.08M | 0.00 | 35.63M |
AcouSort AB Technical Analysis
Positive
2.64
Price Trends
3.47
Positive
3.05
Positive
3.02
Positive
Market Momentum
0.43
Negative
70.87
Negative
94.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Positive. The current price of 2.64 is below the 20-day moving average (MA) of 4.23, below the 50-day MA of 3.47, and below the 200-day MA of 3.02, indicating a bullish trend. The MACD of 0.43 indicates Negative momentum. The RSI at 70.87 is Negative, neither overbought nor oversold. The STOCH value of 94.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ACOU.
AcouSort AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | kr378.80M | -4.87 | -264.12% | ― | 147.35% | ― | |
53 Neutral | kr105.61M | -5.90 | -79.59% | ― | 44.67% | 33.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr77.43M | ― | -601.02% | ― | 45.42% | -24.68% | |
47 Neutral | kr99.46M | -2.16 | -202.18% | ― | ― | -62.18% | |
43 Neutral | kr45.54M | -1.97 | ― | 8.47% | ― | ― | |
41 Neutral | kr65.05M | -1.65 | -88.65% | ― | 21.37% | 27.89% |
* Healthcare Sector Average
SE:ACOU
AcouSort AB
4.82
1.52
46.06%
SE:PILA
PILA PHARMA AB
1.65
-1.27
-43.59%
SE:ONCOZ
OncoZenge AB
7.28
2.13
41.36%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
1.81
-6.71
-78.75%
SE:LARK
CombiGene AB
2.32
0.07
2.93%
SE:SPRINT
Sprint Bioscience AB
3.27
2.80
597.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.